A Long-Term Study To Examine The Effects Of CP-945,598 On Weight Loss And Safety
Phase 3
Terminated
- Conditions
- Obesity
- Interventions
- Drug: CP-945,598 Treatment ADrug: CP-945,598 Treatment BDrug: Placebo
- Registration Number
- NCT00375401
- Lead Sponsor
- Pfizer
- Brief Summary
The purpose of this study is to examine the long-term weight loss and safety of CP-945,598 in obese adults
- Detailed Description
The CP-945,598 program was terminated on November 3, 2008 due to changing regulatory perspectives on the risk/benefit profile of the CB1 class and likely new regulatory requirements for approval. No safety issues were involved in the termination decision.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 2536
Inclusion Criteria
- Obese adults with a body mass index > or = 30 kg/m2; > or = to 27 kg/m2 for those with obesity-related comorbidities including hypertension and dyslipidemia
Read More
Exclusion Criteria
- Pregnancy
- Diabetes
- Adults with serious or unstable current or past medical conditions
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description CP-945,598 Treatment A CP-945,598 Treatment A - CP-945,598 Treatment B CP-945,598 Treatment B - Placebo Placebo -
- Primary Outcome Measures
Name Time Method Proportion of subjects with 5% weight loss 1 year Change in body weight 1 year
- Secondary Outcome Measures
Name Time Method Blood pressure, blood lipids and glucose, waist circumference, quality of life 2 years
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇨🇦Montreal, Quebec, Canada